No information available. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
This antibody blocks the cleavage of the complement protein C5 and thereby prevents the formation of C5a and the membrane attack complex, which lowers the risk of blood clot formation and intravascular hemolysis, the most common thrombotic complications underlying mortality in PNH patients. Chronic uncontrolled activation of the complement system also plays a major role in the debilitating symptoms and potentially life-threatening complications for anti-AchR antibody-positive gMG patients. Ecilizumab effectively inhibits the terminal complement cascade and directly targets this critical underlying cause of gMG. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |